Navigation Links
L&M Healthcare Communications LLC Expands With Hiring of New Executive Staff & Opening of Midwest Office
Date:6/4/2008

Independent Medical Education Agency Enhances Offerings

MOUNTAINSIDE, N.J., June 4 /PRNewswire/ -- L&M Healthcare Communications LLC, an independent, full-service medical education company, announces the opening of a new full-service Midwest office in Milwaukee, Wis. and the hiring of Todd Graverson as Vice President, Client Services.

These enhancements allow L&M Healthcare Communications to expand their service offerings and better meet the needs of their growing client portfolio. Todd Graverson brings more than eight years of experience in pharmaceutical marketing and market research to L&M, where he will spearhead Client Services. Prior to joining L&M, Graverson served as a Sr. Product Manager for Schwarz Pharma.

"We are thrilled to expand our capabilities with the hiring of Todd and the opening of our new Midwest office," said Lenny LaManna, DPM, Partner at L&M Healthcare Communications. "Having offices in both the Midwest and East coast, two of the largest pharmaceutical and biotech development spaces, allows us to quickly respond to the needs of our clients. Additionally, Todd's years of experience in pharmaceutical marketing make him a valuable resource for our customers, adding a new set of offerings to our company."

The staff at L&M has nearly 100 years of experience in healthcare communications in a variety of therapeutic areas including central nervous system diseases, dermatologic conditions, wound healing, oncology, women's health, gastroenterology, urology and cardiology. This experience, plus the company's commitment to client service, is what differentiates L&M from other agencies.

"Adaptability and experience are the cornerstones of great medical education," notes Adam Margolis, Partner at L&M Healthcare Communications. "Our team of experienced and highly strategic account service and scientific staff are well-positioned to actively partner with clients in the pre-launch, launch and post-launch phases
'/>"/>

SOURCE L&M Healthcare Communications LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
3. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
4. Dr. Paul Bandt Celebrates 35th Anniversary With Desert Radiologists and a History of Healthcare in Las Vegas
5. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
6. MDS to Present at Thomas Weisel Partners Healthcare Conference
7. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
8. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Kingfisher Healthcare (KFH) Achieves World Class Quality Platform
11. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...researchers remain cautious about future antibioti...RIDAY, Nov. 21 (HealthDay News) -- People with mod...ase (COPD) may be able to reduce the frequency of ...mon antibiotic, a new report says. , The study... American Journal of Respiratory and Critical Car...
(Date:11/21/2008)...TON, Nov. 21 The Unive...d the beginning of a collaborative effort to eradi...ip for Breast Cancer Awareness and Research of the...irst Lady of the United States, and Vivian Fernand... Joining M. D. Anderson in the initiative are th...
(Date:11/21/2008)...% Shareholders Intend To Vigorously Protect Invest...INNATI, Nov. 21 Dr. Ste...ed an amendment to their Schedule 13D with the U.S...reviously filed a 13D disclosing ownership of 11.4...rates 77 LasikPlus fixed-site laser vision correct...
(Date:11/21/2008)...KLIN LAKES, N.J., Nov. 21 /PRNewswire-FirstCall/ -...or medical intervention in treating 88 percent of ...cent of Americans treated for a chronic condition ...ending and 75 percent of all medical costs. A pro...ears by Medco Health Solutions, Inc. (NYSE: MHS ...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6
...cording to American research, the most effective w...ysiology . Lead author David Ludwig, director of ...Hospital Boston, who says that 'This study shows t...l', also notes that heavy people with an apple sha...
...new study of chemo patients, scientists at the Geo...r Institute has revealed that a gene , p53, though...cer cells, may actually help them thrive. The res...bjects whose tumors had mutations in the gene p53 ...
...new study has shown that cigarette smoking is more...hol consumption . The study, published in the Jo...t a quarter of head and neck cancers among non-dri...g. Led by Dr. Mia Hashibe of the International A...
...new study by researchers from the National Evoluti...US, has revealed how reproductive speed prevents ...hat are regularly hunted by humans, from becoming ...ough habitat loss and living in a limited geograph...
Other Medicine News:Health News:Check Your Physiology Before You Choose A Diet 2Health News:Gene Thought to Help Kill Cancer Cells may Actually Help Them Thrive 2Health News:Extinction Risk of Grazing Animals Depends on Reproductive Speed 2
(Date:11/20/2008)...ewswire/ -- The following is being released by Cen...AT: World AIDS Day Audio Media Conference , ... 11:00 a.m. EST , Call-in number: 1-800-949-847...talk.com/r/1xe41i2yre8rs , , WHY: With n...ewly put on treatment worldwide, advocates are cal...
(Date:11/20/2008)...A, Nov. 20 GlaxoSmithKlin...tates Food and Drug Administration (FDA) granted a...for the treatment of thrombocytopenia in patients ...purpura (ITP) who have had an insufficient respons...my. The approval is a significant milestone for PR...
(Date:11/20/2008)...20 Arpida (SWX:,ARPN) a...ory Committee of the,U.S. Food and Drug Administr...l of intravenous iclaprim, an antibiotic currently...h complicated skin and skin structure infections,...sistant Staphylococcus,aureus (MRSA). , Ar...
(Date:11/20/2008)...wire-FirstCall/ -- Bionovo, Inc.,(Nasdaq: BNVI ...the Phase 1B,clinical trial of their lead drug ca...L101, at the Society for Integrative Oncology,s Fi... The Company,s oral presentation was selected,as... part of the Best of the,SIO Session on November ...
Breaking Medicine Technology:Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5New surgery improves head and neck cancer treatment 3113 1New surgery improves head and neck cancer treatment 3113 2Too Few Cancer Survivors Pursue Healthy Lifestyles 18009 1Too Few Cancer Survivors Pursue Healthy Lifestyles 18009 2Too Few Cancer Survivors Pursue Healthy Lifestyles 18009 3Media Alert 3A 100 Black Men of Atlanta Host 3rd Annual Community Health Fair 18006 1Media Alert 3A 100 Black Men of Atlanta Host 3rd Annual Community Health Fair 18006 2InfoLogix Announces First Quarter 2008 Financial Results 18003 1InfoLogix Announces First Quarter 2008 Financial Results 18003 2InfoLogix Announces First Quarter 2008 Financial Results 18003 3InfoLogix Announces First Quarter 2008 Financial Results 18003 4InfoLogix Announces First Quarter 2008 Financial Results 18003 5InfoLogix Announces First Quarter 2008 Financial Results 18003 6InfoLogix Announces First Quarter 2008 Financial Results 18003 7InfoLogix Announces First Quarter 2008 Financial Results 18003 8InfoLogix Announces First Quarter 2008 Financial Results 18003 9
... MARKHAM, ON, June 28, 2007 /PRNewswire/ - Cytoch...se I clinical trial of,CTA018 Injection. The initi...A018 was safe and well tolerated. Complete study,r... completed Phase I trial was an open label,placeb...,administered to 20 healthy volunteers. In this tr...
... WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 -...rity owned subsidiary of,Accentia Biopharmaceutica... blinded interim data from the start of its fast-t...TM) for Non-Hodgkin,s,lymphoma (NHL) from Septembe...a is the most recent data that has been made avail...
Other Medicine Technology:Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 2Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 3Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 2Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 3Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 4Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 5
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: